Alto Neuroscience (ANRO) Change in Cash (2023 - 2026)

Alto Neuroscience (ANRO) has 4 years of Change in Cash data on file, last reported at $87.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 1267.6% year-over-year to $87.3 million; the trailing twelve-month figure through Mar 2026 stood at $103.0 million (up 330.75% YoY), and the FY2025 full-year result was $8.3 million, down 90.42% from the prior year.
• Change in Cash advanced to $87.3 million in Q1 2026, from $38.7 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $123.3 million in Q1 2024 to a low of -$13.5 million in Q4 2024.
• A 4-year average of $16.6 million and a median of -$7.5 million in 2025 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash tumbled 143.1% in 2024 and jumped 1267.6% in 2026, its largest moves.
• Tracing ANRO's Change in Cash over 4 years: stood at $31.3 million in 2023, then tumbled by 143.1% to -$13.5 million in 2024, then soared by 387.02% to $38.7 million in 2025, then soared by 125.71% to $87.3 million in 2026.
• Business Quant data shows ANRO's Change in Cash at $87.3 million in Q1 2026, $38.7 million in Q4 2025, and -$9.8 million in Q3 2025.